U

UroGen Pharma Ltd
D

URGN

12.520
USD
0.01
(0.08%)
مغلق
حجم التداول
21,626
الربح لكل سهم
-3
العائد الربحي
-
P/E
-4
حجم السوق
528,336,663
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AGIO
    -1.645
    (-2.97%)
    53.810 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EXAS
    -1.680
    (-3.29%)
    49.330 USD
    F
    FGEN
    -0.03530
    (-9.54%)
    0.33460 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    N
    NVCR
    -0.470
    (-2.83%)
    16.120 USD
    T
    TNDM
    -1.240
    (-4.34%)
    27.330 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    466.72 USD
    المزيد
الأخبار

العنوان: UroGen Pharma Ltd

القطاع: Healthcare
الصناعة: Biotechnology
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.